Reticulocyte & Red Cell Patents: Who Leads, Where Gaps Are 2026
Reticulocyte and Red Cell Parameter Patents: Concentration, Trend and Open Ground
33.2% concentration at the top. The five leading assignees combined account for 631 of the 1,903 records in scope, with a long tail of single- and few-filing entrants below them. Filings peaked in 2017 at 121 and have since declined, reaching 66 in 2021 and 29 in 2024 — a -56% move over that span. Treat 2025 and 2026 figures as provisional; they will rise as more publications clear the roughly 18-month lag between filing and disclosure.
- 1ACCELERON PHARMA INC339
- 2FIBROGEN INC95
- 3AMBRX INC92
- 4SYSMEX CORP53
- 5BAYER CORP52
See the full reticulocyte and red cell parameters analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on reticulocyte and red cell parameter patents
Who are the leading patent holders in reticulocyte and red cell parameter technology?
The dataset’s assignee ranking shows a steep concentration at the top: the leading assignee holds 339 of the 1,903 records in scope, well ahead of the fifth-ranked assignee at 52 and tenth-ranked at 44. Together the top five assignees hold 33.2% of all records, and the top ten hold 45.8%. Below that top tier, filings spread across a long tail of assignees with far fewer records each, spanning both erythropoiesis-stimulating biologics developers and diagnostic instrument makers.
Is patent filing activity in this field growing or shrinking?
Filing peaked in 2017 at 121 records and has declined since, falling to 66 in 2021 and 29 in 2024 — a -56% change over that three-year span. However, publication typically lags actual filing by around 18 months, so the 2025 and 2026 figures in this dataset are still incomplete and should not be read as confirming a continued decline. The safest complete-year comparison currently available is the 2021-to-2024 window.
What technology areas do these patents cover?
The IPC composition shows A61K (medicinal preparations) touching 57.2% of the 1,903 records and A61P (therapeutic activity) touching 36.5%, indicating a strong weighting toward erythropoiesis-related drug claims. C07K (peptides and proteins) and G01N (material analysis and testing) each cover roughly 30% of records, capturing biologic composition and diagnostic assay work respectively. Smaller shares in C12N, C12Q, C12P and G06F mark genetic engineering, enzymatic and data-processing sub-areas as comparatively less claimed.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Reticulocyte and Red Cell Parameters covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.